Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed and recurrent setting. We present a case of r...

Full description

Saved in:
Bibliographic Details
Published inJIM - high impact case reports Vol. 10; pp. 232470962211271 - 23247096221127114
Main Authors Ashok Kumar, Prashanth, Ombada, Mulham, Pemmasani, Gayatri, Tambe, Ajay, Banki, Katalin, Gentile, Teresa
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 2022
Sage Publications Ltd
SAGE Publishing
Subjects
Case Report
Case reports
Dendritic cells
Leukemia
Tumors
liposomal daunorubicin and cytarabine
vyxeos
acute myeloid leukemia
blastic plasmacytoid dendritic cell neoplasm
Online AccessGet full text

Cover

More Information
Summary:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed and recurrent setting. We present a case of refractory BPDCN in a 62-year-old man who showed a complete bone marrow response to liposomal daunorubicin and cytarabine (vyxeos).
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2324-7096
2324-7096
DOI:10.1177/23247096221127114